| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| Other Sizes |
| ln Vivo |
The effect of lactose consumption on the bowel habits of elderly constipated patients was investigated. The study involved 15 female subjects with a mean age of 76.4 years. Participants consumed their regular hospital diet supplemented with lactose. The dosage regimen was 20 g/d for 8 days, followed by a 3-day adaptation period where the dose was increased stepwise to 40 g/d, which was then maintained from day 12 to 19. The 20-g dose was administered once at 0800 in 250 mL water, while the 40-g dose was split into two 20-g portions given at 0800 and 1600. The response to lactose was highly variable. In 4 out of 15 subjects, 20 g/d lactose increased stool frequency to 3-4 per week, and 40 g/d further increased it to 7.5 per week. In seven other subjects, only the 20 g/d dose increased stool frequency (to one per day), while 40 g/d reduced it to 2-3 per week, leading to firmer stools and defecation problems. Four of these seven patients reported moderate abdominal pain. Four subjects experienced only minor laxative effects regardless of the dose (2-3 bowel movements/week) and complained about severe flatus. The percentage of fecal dry matter decreased significantly from baseline after consuming 20 g/d lactose (from 32.3% ± 6.3% to 28.4% ± 6.4%, p<0.05), an effect also observed at the 40 g/d dose (27.3% ± 5.5%, p<0.05), corresponding to an increase in stool water content [1].
|
|---|---|
| Enzyme Assay |
Fecal β-glucosidase and β-glucuronidase activities were measured photometrically by following the hydrolysis of the chromogenic substrates p-nitrophenyl-β-glucopyranoside and p-nitrophenyl-β-D-glucuronide, respectively. Enzyme activity was expressed as the amount of enzyme that hydrolyzes 1 μmol of substrate per minute per mg of fecal dry mass at 37°C. No significant changes in the fecal activities of these enzymes were observed in response to feeding lactose at either 20 g/d or 40 g/d compared to baseline [1].
|
| ADME/Pharmacokinetics |
Lactose, a disaccharide, becomes available to the colonic microflora for fermentation. This occurs primarily in cases of specific disaccharide deficiencies, defects in the corresponding transport system, or if the amount of sugar ingested exceeds the maximal rate of absorption in the small intestine, leading to its spillover into the large intestine [1].
|
| Toxicity/Toxicokinetics |
Interactions
Rats fed a diet containing 40% lactose for 5 days showed higher total cholesterol levels in their livers compared to the control group fed a basal sucrose diet. The lactose-added diet significantly reduced fecal sterol production, suggesting this result may be related to cholesterol absorption. Quantitative balance studies showed that the sucrose control group absorbed 40.4% of the administered cholesterol, while the lactose group absorbed 66.2% of the same dose. When lactose was added to the diet, both 2% and 4% calcium chloride inhibited cholesterol absorption; however, when sucrose was added, up to 4% calcium chloride was required to produce a similar effect… The ingestion of lactose as a dietary supplement in elderly constipated patients was associated with several adverse effects. While 20 g/d showed a laxative effect in some, a higher dose of 40 g/d in some subjects led to firmer stools and defecation problems. Furthermore, side effects such as flatulence, intestinal pressure, and abdominal pain were reported by some patients. Specifically, four out of fifteen patients complained about severe flatus, and four others reported moderate abdominal pain during lactose consumption [1]. |
| References | |
| Additional Infomation |
Lactose is a white, hard crystalline powder. (NTP, 1992)
β-lactose is the β-isomer of lactose. It is a disaccharide composed of glucose and galactose, found in human and cow's milk. It is used in pharmaceuticals as tablets, in medicine as a nutrient, and in industry. It has been reported that St. John's wort contains β-lactose, and there is relevant data. It is a disaccharide composed of glucose and galactose, found in human and cow's milk. It is used in pharmaceuticals as tablets, in medicine as a nutrient, and in industry. Lactose has been historically recommended for the treatment of a variety of gastrointestinal disorders, including constipation. In this study, its effectiveness in treating constipation was investigated and compared to inulin. The study confirmed that the intestinal microflora of elderly patients is affected by the intake of lactose. In individuals consuming lactose, a noticeable increase in fecal counts of enterococci (from log₁₀ 7.1 ± 1.1 to 8.1 ± 1.2 CFU/g dry feces, p<0.01) and a decrease in lactobacilli (from log₁₀ 7.9 ± 0.9 to 7.0 ± 1.0 CFU/g dry feces, p<0.05) and clostridia (from log₁₀ 6.4 ± 1.2 to 5.6 ± 0.8 CFU/g dry feces, p<0.05) was detected. In 5 of 15 patients receiving 40 g lactose/d, Bacteroides species increased by approximately 2 logs. The study suggests that the laxative effect of lactose is highly variable among individuals and can be accompanied by significant discomfort [1]. |
| Exact Mass |
342.116
|
|---|---|
| CAS # |
63-42-3
|
| PubChem CID |
6134
|
| Appearance |
White, hard, crystalline mass of white powder
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
667.9±55.0 °C at 760 mmHg
|
| Melting Point |
222.8°C
|
| Flash Point |
357.8±31.5 °C
|
| Vapour Pressure |
0.0±4.6 mmHg at 25°C
|
| Index of Refraction |
1.652
|
| LogP |
-3.41
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
23
|
| Complexity |
382
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2O)O)O)CO)O)O)O)O
|
| InChi Key |
GUBGYTABKSRVRQ-DCSYEGIMSA-N
|
| InChi Code |
InChI=1S/C12H22O11/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17/h3-20H,1-2H2/t3-,4-,5+,6+,7-,8-,9-,10-,11-,12+/m1/s1
|
| Chemical Name |
(2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol
|
| Synonyms |
Lactose, anhydrous Lactose Galactinum Fast-flo
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~292.14 mM)
DMSO : ~50 mg/mL (~146.07 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.30 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.30 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.30 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 130 mg/mL (379.78 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT06724705
Conditions:Lactose Intolerance, Adult TypeLink: https://clinicaltrials.gov/ct2/show/NCT02584439
Conditions:Healthy|Vascular Stiffness|AgingLink: https://clinicaltrials.gov/ct2/show/NCT03582176
Conditions:Elbow Fracture|Elbow Injury|Elbow Dislocation
Title:Human Cerebral Blood Flow Regulation
Status:Completed
updateDate:2025-10-03
Ctid:NCT04265053
Link: https://clinicaltrials.gov/ct2/show/NCT04265053
Conditions:Cerebral Arterial DiseasesLink: https://clinicaltrials.gov/ct2/show/NCT06746285
Conditions:Gastrointestinal Tolerance of Probiotics in InfantsLink: https://clinicaltrials.gov/ct2/show/NCT01404754
Conditions:Psychological Effects of Study DrugLink: https://clinicaltrials.gov/ct2/show/NCT04924530
Conditions:Cardiovascular Risk Factor|Lipaemia|Metabolic DiseaseLink: https://clinicaltrials.gov/ct2/show/NCT02999022
Conditions:FracturesLink: https://clinicaltrials.gov/ct2/show/NCT00888680
Conditions:MigraineLink: https://clinicaltrials.gov/ct2/show/NCT01041755
Conditions:Hepatic EncephalopathyLink: https://clinicaltrials.gov/ct2/show/NCT03497598
Conditions:Urinary Tract InfectionsLink: https://clinicaltrials.gov/ct2/show/NCT01434745
Conditions:Smith-Lemli-Opitz SyndromeLink: https://clinicaltrials.gov/ct2/show/NCT00876161
Conditions:HealthyLink: https://clinicaltrials.gov/ct2/show/NCT03878511
Conditions:Bacterial VaginosesLink: https://clinicaltrials.gov/ct2/show/NCT01550107
Conditions:SarcopeniaLink: https://clinicaltrials.gov/ct2/show/NCT02042521
Conditions:Nicotine Dependence, Cigarettes, With WithdrawalLink: https://clinicaltrials.gov/ct2/show/NCT01644877
Conditions:ParainfluenzaLink: https://clinicaltrials.gov/ct2/show/NCT01723592
Conditions:Breast CancerLink: https://clinicaltrials.gov/ct2/show/NCT03121222
Conditions:Glutathione Metabolism AnemiasLink: https://clinicaltrials.gov/ct2/show/NCT02636413
Conditions:Lactose IntoleranceLink: https://clinicaltrials.gov/ct2/show/NCT01675986
Conditions:Feeling AnxiousLink: https://clinicaltrials.gov/ct2/show/NCT02787707
Conditions:Nausea|VomitingLink: https://clinicaltrials.gov/ct2/show/NCT02566798
Conditions:OsteoarthritisLink: https://clinicaltrials.gov/ct2/show/NCT02596360
Conditions:Experimental Pain|HyperalgesiaLink: https://clinicaltrials.gov/ct2/show/NCT02448940
Conditions:Overweight and ObesityLink: https://clinicaltrials.gov/ct2/show/NCT01848119
Conditions:PainLink: https://clinicaltrials.gov/ct2/show/NCT02214095
Conditions:Chronic PeriodontitisLink: https://clinicaltrials.gov/ct2/show/NCT02172508
Conditions:Pulmonary Disease, Chronic ObstructiveLink: https://clinicaltrials.gov/ct2/show/NCT00980031
Conditions:Myocardial RemodelingLink: https://clinicaltrials.gov/ct2/show/NCT01151306
Conditions:Chronic Obstructive Pulmonary DiseaseLink: https://clinicaltrials.gov/ct2/show/NCT01277237
Conditions:Non Alcoholic Fatty Liver DiseaseLink: https://clinicaltrials.gov/ct2/show/NCT00979056
Conditions:DiarrhoeaLink: https://clinicaltrials.gov/ct2/show/NCT00624754
Conditions:Obstructive Airway DiseaseLink: https://clinicaltrials.gov/ct2/show/NCT01748279
Conditions:COPDLink: https://clinicaltrials.gov/ct2/show/NCT01812967
Conditions:Glycemic Control|Gastrointestinal Hormone Response|Healthy Young MenLink: https://clinicaltrials.gov/ct2/show/NCT01575678
Conditions:Nocturnal EnuresisLink: https://clinicaltrials.gov/ct2/show/NCT01028014
Conditions:Urethral Sphincter ActivityLink: https://clinicaltrials.gov/ct2/show/NCT00682214
Conditions:Vitamin D DeficiencyLink: https://clinicaltrials.gov/ct2/show/NCT01094925
Conditions:PainLink: https://clinicaltrials.gov/ct2/show/NCT01136317
Conditions:Gastroesophageal RefluxLink: https://clinicaltrials.gov/ct2/show/NCT01185418
Conditions:Normal VolunteersLink: https://clinicaltrials.gov/ct2/show/NCT00983177
Conditions:Calcific TendonitisLink: https://clinicaltrials.gov/ct2/show/NCT00599859
Conditions:Lactose IntoleranceLink: https://clinicaltrials.gov/ct2/show/NCT00841230
Conditions:TinnitusLink: https://clinicaltrials.gov/ct2/show/NCT00351117
Conditions:Raynaud's DiseaseLink: https://clinicaltrials.gov/ct2/show/NCT00504946
Conditions:AsthmaProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
